News | February 14, 2023
NATCO files generic Olaparib Tablets in USA
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
_256_384.png)
Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection.
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Study achieves primary endpoint of radiographic progression-free survival
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
Transformation to pure-play Innovative Medicines company nears completion
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
Orion to receive an upfront payment of USD 290 million
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
Subscribe To Our Newsletter & Stay Updated
